lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019

21 Pages Posted: 10 Mar 2020

See all articles by Tao Liu

Tao Liu

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

Jieying Zhang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

Yuhui Yang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

Liling Zhang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

Hong Ma

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

Zhengyu Li

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

Jiaoyue Zhang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Endocrinology

Ji Cheng

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Gastrointestinal Surgery; Harvard University - Department of Pathology

Xiaoyun Zhang

Fudan University - Liver Cancer Institute

Gang Wu

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

Jianhua Yi

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Infectious Diseases

More...

Abstract

Background: The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan City, China spreads rapidly since December, 2019. Most patients show mild symptoms, but some of them develop into severe disease. There is currently no specific medication. The purpose of this study is to explore changes of markers in peripheral blood of severe COVID-19 patients, which may be of value in disease monitoring.

Methods: Clinical data of patients with nonsevere and severe type COVID-19 diagnosed by laboratory test in our institution were collected. The relationship between peripheral blood cells and cytokines, clinical manifestation and outcome was analyzed.

Results: A total of 69 severe type COVID-19 patients were included. On admission, the median age of severe cases was 56-year old, with 52.17% of female patient. The most common symptoms were fever (79.72%), coughing (63.77%), shortness of breath (57.97%) and fatigue (50.72%). Diarrhea is less common. The most common comorbidity is hypertension. Upon admission, the proportion of bilateral pulmonary involvement or interstitial pneumonia evidenced by CT imaging in severe cases was 60.87% and 27.54%, respectively. Compared with patients with nonsevere disease, those with severe disease showed lymphocytopenia. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer was found in most cases. Two patients (2.9%) needed transfer to the intensive care unit. Baseline immunological parameters and most of the inflammatory parameters were basically within the normal range. However, baseline IL-6 was significantly increased in severe type which is closely related to the maximal body temperature during hospitalization and CT findings. Baseline IL-6 was also significantly related to the increase of baseline level of CRP, LDH, ferritin and D-dimer. The increase of baseline IL-6 level suggests that it may positively correlate with the severity of COVID-19. Among the 30 severe type patient whose level of IL-6 was assessed before and after treatment, significant decrease in IL-6 and improved CT assessment was found in 25 patients after treatment. Whereas the IL-6 level was further increased in 3 cases, which was closely related to the progression of pneumonia. It is suggested that IL-6 may be used as a biomarker for disease monitoring in severe COVID-19 patients.

Conclusion: On admission, the baseline level of IL-6, CRP, LDH and ferritin was closely related to the severity of COVID-19, and the high level of IL-6 was significantly related to the clinical manifestation of severe type patients. The decrease of IL-6 was closely related to treatment effectiveness, while the increase of IL-6 indicated disease progression. Collectively, the dynamic change of IL-6 level can be used as a marker for disease monitoring in patients with severe COVID-19.

Funding Statement: This work was supported by the National Natural Science Foundation of China (No. 81602696 to TL) and Science and Technology Major Project of China (No.2018ZX10302204-002-003).

Declaration of Interests: All authors declare no competing interests.

Ethics Approval Statement: This study was approved by the Research Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. Written consent was obtained from patients before the enrollment.

Keywords: Coronavirus disease 2019, interleukin-6

Suggested Citation

Liu, Tao and Zhang, Jieying and Yang, Yuhui and Zhang, Liling and Ma, Hong and Li, Zhengyu and Zhang, Jiaoyue and Cheng, Ji and Zhang, Xiaoyun and Wu, Gang and Yi, Jianhua, The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019 (3/1/2020). Available at SSRN: https://ssrn.com/abstract=3548761 or http://dx.doi.org/10.2139/ssrn.3548761

Tao Liu

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

China

Jieying Zhang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

China

Yuhui Yang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

China

Liling Zhang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

China

Hong Ma

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

China

Zhengyu Li

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

China

Jiaoyue Zhang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Endocrinology

Wuhan, Hubei 430022
China

Ji Cheng

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Gastrointestinal Surgery ( email )

1037 Luoyu Rd
Wuhan
China

Harvard University - Department of Pathology

Boston, MA 02115
United States

Xiaoyun Zhang

Fudan University - Liver Cancer Institute

Shanghai, 200032
China

Gang Wu

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Cancer Center

China

Jianhua Yi (Contact Author)

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Infectious Diseases

Wuhan
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
667
Downloads
172